Strides Pharma Science Ltd

Strides Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Strides Pharma Science Ltd

₹ 908 -1.31%
25 Jul - close price
strides.com BSE: 532531 NSE: STAR
About

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Key Points

Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]

Website BSE NSE
  • Market Cap ₹ 8,370 Cr.
  • Current Price ₹ 908
  • High / Low ₹ 956 / 465
  • Stock P/E 2.38
  • Book Value ₹ 277
  • Dividend Yield 0.44 %
  • ROCE 14.7 %
  • ROE 151 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has delivered good profit growth of 128% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 50.4%

Cons

  • Stock is trading at 3.28 times its book value
  • The company has delivered a poor sales growth of 10.6% over past five years.
  • Promoter holding is low: 28.3%
  • Promoters have pledged or encumbered 50.1% of their holding.
  • Earnings include an other income of Rs.3,313 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
866 940 897 865 986 930 999 1,006 1,044 1,088 1,167 1,154 1,190
868 936 844 892 871 796 889 876 874 882 983 943 973
Operating Profit -1 4 53 -27 115 134 111 129 169 205 184 210 218
OPM % -0% 0% 6% -3% 12% 14% 11% 13% 16% 19% 16% 18% 18%
9 -52 57 68 20 3 -129 60 -27 9 25 4 -12
Interest 49 55 68 58 81 76 79 70 71 80 74 52 50
Depreciation 61 60 62 60 61 60 60 49 48 49 48 48 49
Profit before tax -103 -163 -20 -78 -7 0 -157 70 23 85 86 114 106
Tax % -128% -17% -197% 5% 106% 3,025% -5% 23% 55% 20% 16% 21% 20%
29 -135 19 -82 -14 -9 -149 54 10 68 72 90 86
EPS in Rs 3.25 -15.13 2.53 -8.86 -1.06 -0.79 -14.54 5.40 1.98 7.64 7.81 9.54 8.91
Raw PDF
Upcoming result date: 29 July 2025

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 15m Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,341 1,196 2,861 2,755 2,845 2,178 2,752 3,316 3,070 3,688 3,890 4,565
1,567 967 2,486 2,228 2,448 1,982 2,338 2,779 3,201 3,544 3,362 3,763
Operating Profit -226 229 374 527 398 197 414 537 -131 145 528 803
OPM % -17% 19% 13% 19% 14% 9% 15% 16% -4% 4% 14% 18%
3,281 874 63 291 643 303 -43 109 -112 92 -100 3,313
Interest 109 47 168 183 196 79 156 150 177 261 280 249
Depreciation 56 64 131 126 154 117 174 206 233 243 214 192
Profit before tax 2,890 992 137 509 690 303 42 289 -653 -268 -65 3,675
Tax % 39% 15% 31% 12% 1% -9% 27% 11% -27% -21% 45% 2%
1,767 844 95 446 684 330 31 258 -474 -212 -94 3,598
EPS in Rs 296.43 141.78 12.15 44.71 74.25 36.27 4.06 29.93 -51.25 -22.44 -7.68 389.75
Dividend Payout % 170% 76% 41% 10% 3% 8% 345% 8% 0% -7% -33% 1%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 14%
TTM: 17%
Compounded Profit Growth
10 Years: 15%
5 Years: 128%
3 Years: 157%
TTM: 3668%
Stock Price CAGR
10 Years: 4%
5 Years: 36%
3 Years: 80%
1 Year: 90%
Return on Equity
10 Years: 21%
5 Years: 28%
3 Years: 50%
Last Year: 151%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 60 60 89 89 90 90 90 90 90 90 92 92
Reserves 947 1,085 2,569 2,659 2,374 2,559 2,438 2,687 2,269 2,122 2,034 2,460
547 892 3,542 3,700 2,520 3,221 2,235 2,348 3,025 3,030 2,517 1,880
543 438 1,211 1,598 1,601 1,937 1,369 1,844 1,556 1,352 1,157 1,498
Total Liabilities 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,929
555 701 2,679 2,980 2,977 3,648 2,099 2,219 2,347 2,311 1,865 1,899
CWIP 99 171 815 780 620 453 413 447 291 151 162 207
Investments 443 630 1,341 1,525 588 702 549 697 540 490 303 409
999 972 2,576 2,762 2,400 3,005 3,070 3,605 3,762 3,642 3,470 3,414
Total Assets 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,929

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-272 83 73 288 187 60 205 481 -258 44 701 684
4,044 50 -2,205 -1,222 570 -145 1,321 -522 -119 302 -150 -90
-3,319 -421 2,944 338 -1,016 194 -1,709 -16 421 -214 -693 -643
Net Cash Flow 454 -288 812 -596 -259 110 -184 -56 45 133 -142 -48

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 99 119 132 132 113 165 124 122 144 129 107 96
Inventory Days 90 135 149 209 146 294 254 329 285 257 235 236
Days Payable 137 153 188 221 188 299 259 323 260 220 178 190
Cash Conversion Cycle 52 102 92 120 71 160 119 128 168 165 164 141
Working Capital Days 53 -29 96 63 117 155 95 94 210 156 147 125
ROCE % 113% 57% 8% 11% 16% 2% 5% 8% -5% -0% 7% 15%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
31.08% 30.90% 28.28% 28.08% 27.79% 27.39% 25.88% 25.86% 25.84% 26.82% 28.30% 28.30%
21.43% 18.98% 18.85% 16.72% 17.25% 19.45% 24.57% 26.71% 30.08% 28.48% 28.32% 28.02%
15.07% 18.44% 17.88% 19.60% 19.50% 19.02% 17.66% 18.17% 18.24% 16.92% 13.72% 13.30%
0.40% 0.40% 0.40% 0.40% 0.40% 0.39% 0.39% 0.39% 0.01% 0.01% 0.01% 0.01%
32.05% 31.29% 34.60% 35.22% 35.06% 33.75% 31.52% 28.87% 25.83% 27.78% 29.65% 30.38%
No. of Shareholders 1,30,6821,23,9641,20,9161,12,7751,01,63891,18284,69591,91796,0091,14,23695,12592,889

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls